Log in to save to my catalogue

Impact of the HLA-DRB1 shared epitope on responses to treatment with tofacitinib or abatacept in pat...

Impact of the HLA-DRB1 shared epitope on responses to treatment with tofacitinib or abatacept in pat...

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_doaj_primary_oai_doaj_org_article_8072e3ec640d40be86ca5bbb0e68cc83

Impact of the HLA-DRB1 shared epitope on responses to treatment with tofacitinib or abatacept in patients with rheumatoid arthritis

About this item

Full title

Impact of the HLA-DRB1 shared epitope on responses to treatment with tofacitinib or abatacept in patients with rheumatoid arthritis

Publisher

London: BioMed Central Ltd

Journal title

Arthritis research & therapy, 2021-08, Vol.23 (1), p.1-228, Article 228

Language

English

Formats

Publication information

Publisher

London: BioMed Central Ltd

More information

Scope and Contents

Contents

Objectives The aim of this study was to compare the clinical effectiveness of tofacitinib and abatacept and clarify the impact of the HLA-DRB1 shared epitope (SE) on responses to these treatments in patients with rheumatoid arthritis (RA). Methods After adjustments by propensity score matching, 70 out of 161 patients receiving tofacitinib and 70 ou...

Alternative Titles

Full title

Impact of the HLA-DRB1 shared epitope on responses to treatment with tofacitinib or abatacept in patients with rheumatoid arthritis

Identifiers

Primary Identifiers

Record Identifier

TN_cdi_doaj_primary_oai_doaj_org_article_8072e3ec640d40be86ca5bbb0e68cc83

Permalink

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_doaj_primary_oai_doaj_org_article_8072e3ec640d40be86ca5bbb0e68cc83

Other Identifiers

ISSN

1478-6362,1478-6354

E-ISSN

1478-6362

DOI

10.1186/s13075-021-02612-w

How to access this item